SorianoV., ArastéhK., MigroneH.Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther2011; 16: 339–348.
2.
PodzamczerD., Andrade-VillanuevaJ., ClotetB.Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naive HIV-1-infected patients (the ARTEN study). HIV Med2011; 12: 374–382.
3.
JohnsonJ.A., LiJ., WeiX.Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med2008; 5: e158.
